Literatur
- 1
Ablin D S, Ziegler M.
Ulcerative type of colitis associated with the use of high strength pancreatic
enzyme supplements in cystic fibrosis.
Pediatr Radiol.
1995;
25
113-115
- 2
Allen M, Mellow M, Robinson M G, Orr W C.
Comparison of calcium channel blocking agents and an anticholinergic agent on
oesophageal function.
Aliment Pharmacol Ther.
1987;
1
153-159
- 3
Allison M C, Howatson A G, Torrance C J.
Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory
drugs.
N Engl J Med.
1992;
327
749-754
- 4
Andersen V, Sonne J, Andersen M.
Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999.
Eur J Clin Pharmacol.
2001;
57
517-521
- 5
Arzneimittelkommission der Deutschen Ärzteschaft .
Zur Sicherheit von COX-2-Inhibitoren.
Dtsch Ärztebl.
2002;
99
1291-1292
- 6
Ballinger A B, Smith G.
COX-2 vs NSAIDs: gastrointestinal damage and prevention.
Exp Opin Pharmacother.
2001;
2
31-40
- 7
Bansi D S, Price A, Russell C, Sarner M.
Fibrosing colonopathy in an adult owing to overuse of pancreatic enzyme supplements.
Gut.
2000;
46
283-285
- 8
Bombardier C, Laine L, Reicin A. et al. VIGOR study group .
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients
with rheumatoid arthritis.
N Engl J Med.
2000;
343
1520-1528
- 9
Boyce H W.
Drug-induced esophageal damage: diseases of medical progress.
Gastrointest Endosc.
1998;
47
547-550
- 10
Byrne M F, McGuiness J, Smyth C M. et al .
Nonsteroidal anti-inflammatory drug-induced diaphragms and ulceration in the
colon.
Eur J Gastroenterol Hepatol.
2002;
14
1265-1269
- 11
Chan F KL, Chung S CS, Suen R N. et al .
Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter
pylori infection who are taking low-dose aspirin or naproxen.
N Engl J Med.
2001;
344
967-973
- 12
Chocarro Martinez A, Galindo Tobal F, Ruiz-Irastorza G. et al .
Risk factors for esophageal candidiasis.
Eur J Clin Microbiol Infect Dis.
2000;
19
96-100
- 13
De Abajo F J, Garcia Rodriguez L A, Montero D.
Association between selective serotonin reuptake inhibitors and upper gastrointestinal
bleeding: population-based case-control study.
Br Med J.
1999;
319
1106-1109
- 14
El-Serag H B, Sonnenberg A.
Association of esophagitis and esophageal strictures with diseases treated with
non-steroidal anti-inflammatory drugs.
Am J Gastroenterol.
1997;
92
52-56
- 15
De Groen P C, Lubbe D F, Laurence C B.
Esophagitis associated with the use of alendronate.
N Engl J Med.
1996;
335
1016-1021
- 16
Garcia Rodriguez L A, Hernandez-Diaz S, De Abajo F J.
Association between aspirin and upper gastrointestinal complications: systematic
review of epidemiologic studies.
Br J Clin Pharmacol.
2001;
52
563-571
- 17
Garcia Rodriguez L A, Hernandez-Diaz S.
Relative risk of upper gastrointestinal complications among users of acetaminophen
and nonsteroidal anti-inflammatory drugs.
Epidemiology.
2001;
12
570-576
- 18
Hawkey C J, Langman M JS.
Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary
roles for COX-2 inhibitors and proton pump inhibitors.
Gut.
2003;
52
600-608
- 19
Ishikawa H, Iwakiri K, Sugiura T, Kobayashi M.
Effect of nifedipine administration (10 mg) on esophageal acid exposure.
J Gastroenterol.
2000;
35
43-46
- 20
Jaspersen D.
Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and
management.
Drug Saf.
2000;
22
237-249
- 21
Jaspersen D.
Extragastrale Nebenwirkungen nicht steroidaler Antirheumatika.
Dtsch Med Wochenschr.
1998;
132
669-673
- 22
Kikendall J W, Mellow M H.
Effect of sublingual nitroglycerin and long-acting nitrate preparations on esophageal
motility.
Gastroenterology.
1980;
79
703-706
- 23
Kikendall J W.
Pill esophagitis.
J Clin Gastroenterol.
1999;
28
298-305
- 24
Langman M J, Weil J, Wainwright G HT P. et al .
Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory
drugs.
Lancet.
1994;
343
1075-1078
- 25
Lankisch P G, Droege M, Gottesleben F.
Drug-induced acute pancreatitis: incidence and severity.
Gut.
1995;
37
565-567
- 26
Larkai E N, Smith J L, Lidsky M D, Graham D Y.
Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic
nonsteroidal anti-inflammatory drug use.
Am J Gastroenterol.
1987;
82
1153-1158
- 27
Lewis S C, Langman M J, Laporte J R, Matthews J N, Rawlins M D, Wiholm B E.
Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory
drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis
based on individual patient data.
Br J Clin Pharmacol.
2002;
54
320-326
- 28
Limmer S, Ittel T H, Wietholz H.
Sekundär- und Primärprophylaxe der ASS-/NSAR-Gastropathie: Eine Übersicht anhand
vier klinischer Szenarien.
Z Gastroenterol.
2003;
41
719-728
- 29
Lloyd-Still J D.
Cystic fibrosis and colonic strictures: a new ‘iatrogenic’ disease.
J Clin Gastroenterol.
1995;
21
2-5
- 30
Mallory A, Kern F.
Drug-induced pancreatitis: a critical review.
Gastroenterology.
1980;
78
813-820
- 31
Makins R, Ballinger A.
Gastrointestinal side effects of drugs. Expert Opin.
Drug Saf.
2003;
2
421-429
- 32
McArthur K E.
Drug-induced pancreatitis.
Aliment Pharmacol Ther.
1996;
10
23-27
- 33
Milminick T, Frick T W.
Drug-induced pancreatitis.
Drug Saf.
1996;
14
406-409
- 34
Nassar N N, Gregg C R.
Oesophageal infections.
Curr Treat Options Gastroenterol.
1998;
1
56-63
- 35
Pemberton J.
Oesophageal obstruction and ulceration caused by oral potassium therapy.
Br Heart J.
1970;
32
267-268
- 36
Petersen K U, Jaspersen D.
Medication-induced esophageal disorders. Expert Opin.
Drug Saf.
2003;
5
1-13
- 37
Ratnaike R N, Jones T E.
Mechanisms of drug-induced diarrhoea in the elderly.
Drugs Aging.
1998;
13
245-253
- 38
Rünzi M, Layer P.
Drug-associated pancreatitis: facts and fiction.
Pancreas.
1996;
13
100-109
- 39
Simon L S, Weaver A L, Graham D Y. et al .
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid
arthritis: a randomized controlled trial.
JAMA.
1999;
282
1921-1928
- 40
Silverstein F E, Faich G, Goldstein. et al .
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs
for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled
trial. Celecoxib Long-term Arthritis Safety Study.
JAMA.
2000;
284
1247-1255
- 41
Smale S, Tibble J, Sigthorsson G, Bjarnason I.
Epidemiology and differential diagnosis of NSAID-induced injury to the mucosa
of the small intestine.
Best Pract Res Clin Gastroenterol.
2001;
15
723-738
- 42
Smyth R L, van Velzen D, Smyth R A. et al .
Strictures of the ascending colon in cystic fibrosis and high-strength pancreatic
enzyme supplements.
Lancet.
1994;
343
85-86
- 43 Stein J, Schröder O. Antibiotikaassoziierte Kolitis - Eine relevante Krankheit?. Urban
und Schwarzenberg, München In: Klinik der Gegenwart, Gerock W, Schöllermich
J (HRSG) 1997: 1-26
- 44
Thumshirn M, Fried M.
Prophylaxe und Therapie NSAR-induzierter Ulzera: ein Update.
Dtsch med Wochenschr.
2000;
125
975-978
- 45
Vanek V W, Al-Salti M.
Acute pseudo-obstruction of the colon (Ogilvie’s syndrome). An analysis of 400
cases.
Dis Colon Rectum.
1986;
29
203-210
- 46
Van Velzen D, Ball L M, Dezfulian A R, Southgate A, Howard C V.
Comparative and experimental pathology of fibrosing colonopathy.
Postgrad Med J.
1996;
72
S39-S48
- 47
Wolfe M M, Lichtenstein D R, Singh G.
Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs.
N Engl J Med.
1999;
340
1888-1899
- 48
Wright J M.
The double-edged sword of COX-2 selective NSAIDs.
Can Med Assoc J.
2002;
167
1131-1137
1 Herrn Prof. Dr. J. F. Riemann gewidmet
Prof. Dr. Daniel Jaspersen
Klinikum Fulda gAG, Med. Klinik II
Pacelliallee 4
36043 Fulda
Email: d.jaspersen.medII@klinikum-fulda.de
